Skip to main content
. 2022 Feb 28;9:847835. doi: 10.3389/fmolb.2022.847835

FIGURE 2.

FIGURE 2

Structures of trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (DS-8201a) and disitamab vedotin (RC-48).